Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294304 | 0.71 | MEN1 (0.64) | MAOAMAOBKDM4EALDH1A1MAPT | |
| SCHEMBL4800801 | 0.70 | SMN1; SMN2 (0.90) | EGFRKDM4EALDH1A1GAARAB9A | |
| SCHEMBL30466257 | 0.67 | SMN1; SMN2 (1.00) | EGFRKDM4EALDH1A1GAARAB9A | |
| SCHEMBL29576858 | 0.67 | SMN1; SMN2 (1.00) | EGFRKDM4EALDH1A1GAARAB9A | |
| SCHEMBL1347142 | 0.67 | SMN1; SMN2 (1.00) | EGFRKDM4EALDH1A1GAARAB9A | |
| SCHEMBL11122272 | 0.66 | PDE5A (0.83) | MAOAMAOBEGFRKDM4EALDH1A1 | |
| SCHEMBL11126048 | 0.66 | PDE5A (0.83) | MAOAMAOBEGFRKDM4EALDH1A1 | |
| SCHEMBL31574503 | 0.65 | MAOA (0.65) | MAOAMAOBKDM4EALDH1A1MAPT | |
| SCHEMBL9628993 | 0.65 | MEN1 (0.78) | MAOAEGFRKDM4EALDH1A1GAA | |
| SCHEMBL10851145 | 0.65 | GAA (0.45) | EGFRKDM4EALDH1A1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752133-B2 | Use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases | Shandong Linghai Biotechnology Co., Ltd. (CN) | 2023-09-12 | — | — | US | disclosed |
| US-11752133-B2 | Use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases | Shandong Linghai Biotechnology Co., Ltd. (CN) | 2023-09-12 | — | — | US | disclosed |
| US-20220193036-A1 | Use of Bromophenol-pyrazoline Compounds in the Treatment of Porcine Coronavirus Diseases | SHANDONG LINGHAI BIOTECHNOLOGY CO., LTD (CN) | 2022-06-23 | — | — | US | disclosed |
| EP-4014975-A1 | USE OF BROMOPHENOL-PYRAZOLINE COMPOUNDS IN THE TREATMENT OF PORCINE CORONAVIRUS DISEASES | Shandong Linghai Biotechnology Co., Ltd. (CN) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193036-A1 | Use of Bromophenol-pyrazoline Compounds in the Treatment of Porcine Coronavirus Diseases | GTF3C3, GTF3C4, GTF3C2 | MAOA 4142/4885MAOB 4125/4885EGFR 4201/4885 |
| US-11752133-B2 | Use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases | GTF3C3, GTF3C4, GTF3C2 | MAOA 4142/4885MAOB 4125/4885EGFR 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.